Key Points
- Fractyl Health CFO Weber Lara Smith bought 20,000 shares of GUTS on June 8 at $0.69 per share, a total purchase of $13,800, and now owns 20,000 shares.
- The company recently reported quarterly EPS of $0.06, beating analyst expectations of a $0.17 loss, though analysts still expect a full-year loss of about $0.60 per share.
- Analyst sentiment is mixed but leans cautious: the stock has an average Hold rating with a $5.40 target price, while institutions such as Rosalind Advisors and 683 Capital Management have recently increased or initiated positions.
Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) CFO Weber Lara Smith purchased 20,000 shares of the stock in a transaction dated Monday, June 8th. The stock was bought at an average cost of $0.69 per share, with a total value of $13,800.00. Following the transaction, the chief financial officer owned 20,000 shares in the company, valued at $13,800. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Fractyl Health Price Performance
GUTS opened at $0.66 on Wednesday. The stock has a 50-day moving average price of $0.67 and a 200-day moving average price of $1.08. The company has a debt-to-equity ratio of 1.41, a current ratio of 4.28 and a quick ratio of 4.28. The firm has a market cap of $105.36 million, a PE ratio of -0.51 and a beta of 2.34. Fractyl Health, Inc. has a 1 year low of $0.38 and a 1 year high of $2.90.
Fractyl Health (NASDAQ:GUTS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.23. Sell-side analysts predict that Fractyl Health, Inc. will post -0.6 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities analysts have weighed in on the company. HC Wainwright reissued a "buy" rating and issued a $8.00 target price on shares of Fractyl Health in a research report on Thursday, June 4th. Canaccord Genuity Group reissued a "buy" rating and issued a $8.00 target price on shares of Fractyl Health in a research report on Thursday, March 26th. Weiss Ratings reissued a "sell (e+)" rating on shares of Fractyl Health in a research report on Tuesday, May 12th. Finally, Wall Street Zen raised Fractyl Health from a "strong sell" rating to a "hold" rating in a research report on Saturday, May 16th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $5.40.
View Our Latest Analysis on GUTS
Institutional Investors Weigh In On Fractyl Health
Large investors have recently made changes to their positions in the company. Rosalind Advisors Inc. bought a new stake in shares of Fractyl Health during the 3rd quarter valued at about $7,950,000. CM Management LLC bought a new position in shares of Fractyl Health during the 3rd quarter valued at approximately $954,000. GSA Capital Partners LLP bought a new position in shares of Fractyl Health during the 3rd quarter valued at approximately $285,000. Accredited Investors Inc. bought a new position in shares of Fractyl Health during the 1st quarter valued at approximately $46,000. Finally, 683 Capital Management LLC grew its stake in shares of Fractyl Health by 30.1% during the 4th quarter. 683 Capital Management LLC now owns 6,047,620 shares of the company's stock valued at $13,305,000 after acquiring an additional 1,397,620 shares during the period.
Fractyl Health Company Profile
(
Get Free Report)
Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.
The company's lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
